Noroxymorphone

Noroxymorphone
Clinical data
Dependence
liability
High
Routes of
administration
Intravenous, intramuscular, subcutaneous, oral, rectal, intranasal
Drug classOpioid
Legal status
Legal status
Identifiers
  • 7,8-Dihydro-14-hydroxynormorphinone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.046.859
Chemical and physical data
FormulaC16H17NO4
Molar mass287.315 g·mol−1
3D model (JSmol)
  • Oc1ccc2C[C@H]3NCC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O
  • InChI=1S/C16H17NO4/c18-9-2-1-8-7-11-16(20)4-3-10(19)14-15(16,5-6-17-11)12(8)13(9)21-14/h1-2,11,14,17-18,20H,3-7H2/t11-,14+,15+,16-/m1/s1
  • Key:HLMSIZPQBSYUNL-IPOQPSJVSA-N

Noroxymorphone is an opioid which is both a metabolite of oxymorphone and oxycodone and is manufactured specifically as an intermediate in the production of opioid antagonists such as naltrexone and others. It is a potent agonist of the μ-opioid receptor, but is poorly able to cross the blood–brain barrier into the central nervous system, and for this reason, has only minimal analgesic activity.

In the United States, noroxymorphone is controlled as a Schedule II Narcotic controlled substance with an ACSCN of 9637. In 2014, the DEA set annual aggregate manufacturing quotas of 17,500 kg for conversion and 1,262.5 kg for sale.